Format

Send to

Choose Destination
Mol Cell Oncol. 2018 Oct 9;5(6):e1509488. doi: 10.1080/23723556.2018.1509488. eCollection 2018.

With great power comes great vulnerability.

Author information

1
Division of Molecular Carcinogenesis & Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Abstract

The clinical responses to targeted drugs are often transient and do not always translate into meaningful overall survival due to the development of resistance. We discuss here that the greater power of drug resistant cells can be associated with significant newly-acquired vulnerabilities that can be exploited therapeutically.

KEYWORDS:

BRAF; drug resistance; histone deacetylase inhibitor; melanoma; reactive oxygen species

PMID:
30525088
PMCID:
PMC6276853
[Available on 2019-10-09]
DOI:
10.1080/23723556.2018.1509488

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center